Updating results

Prostate cancer - intensity modulated radiotherapy [ID17]

In development [GID-TAG396] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

In development [GID-TAG496] Expected publication date: TBC

Technology appraisal guidance In development

Colon cancer (adjuvant) - irinotecan [ID379]

In development [GID-TAG380] Expected publication date: TBC

Technology appraisal guidance In development

Head and neck cancer - contusugene ladenovec [ID76]

In development [GID-TAG407] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small cell) - afatinib [ID357]

In development [GID-TAG422] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

In development [GID-TAG494] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]

In development [GID-TAG330] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer (prevention) - dutasteride [ID75]

In development [GID-TAG409] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer (hormone refractory) - atrasentan [ID390]

In development [GID-TAG379] Expected publication date: TBC

Technology appraisal guidance In development

Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

In development [GID-TAG300] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

In development [GID-TAG440] Expected publication date: TBC

Technology appraisal guidance In development

Diabetes - buccal insulin [ID311]

In development [GID-TAG244] Expected publication date: TBC

Technology appraisal guidance In development

Glaucoma - lerdelimumab (CAT-152) [ID383]

In development [GID-TAG381] Expected publication date: TBC

Technology appraisal guidance In development

Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]

In development [GID-TAG369] Expected publication date: TBC

Technology appraisal guidance In development

Encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer [ID1598]

In development [GID-TA10496] Expected publication date: 21 October 2020

Technology appraisal guidance In development

Osteoarthritis: care and management (update)

In development [GID-NG10127] Expected publication date: 25 August 2021

NICE guideline In development

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm ID1556

In development [GID-TA10482] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Acne Vulgaris: Management

In development [GID-NG10109] Expected publication date: 13 January 2021

NICE guideline In development

Siponimod for treating secondary progressive multiple sclerosis [ID1304]

In development [GID-TA10436] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]

In development [GID-TAG430] Expected publication date: 28 October 2020

Technology appraisal guidance In development

Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 04 April 2022

NICE guideline In development

Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

In development [GID-TA10380] Expected publication date: TBC

Technology appraisal guidance In development

Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)

In development [GID-TA10366] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

In development [GID-TA10271] Expected publication date: TBC

Technology appraisal guidance In development

Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

In development [GID-TA10179] Expected publication date: TBC

Technology appraisal guidance In development

Mastocytosis (systemic) - masitinib [ID781]

In development [GID-TA10019] Expected publication date: TBC

Technology appraisal guidance In development

Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

In development [GID-TA10180] Expected publication date: TBC

Technology appraisal guidance In development

Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

In development [GID-TA10089] Expected publication date: 15 November 2017

Technology appraisal guidance In development

Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

In development [GID-TA10109] Expected publication date: TBC

Technology appraisal guidance In development

Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

In development [GID-TA10024] Expected publication date: 28 June 2017

Technology appraisal guidance In development

Diagnostic services

In development [GID-CGWAVE0773] Expected publication date: TBC

NICE guideline In development

Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

In development [GID-TA10228] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]

In development [GID-TA10110] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

In development [GID-TA10164] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]

In development [GID-TA10272] Expected publication date: TBC

Technology appraisal guidance In development

Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

In development [GID-TA10254] Expected publication date: TBC

Technology appraisal guidance In development

Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

In development [GID-TA10046] Expected publication date: 22 November 2017

Technology appraisal guidance In development

Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

In development [GID-TA10065] Expected publication date: TBC

Technology appraisal guidance In development

Nintedanib for untreated malignant pleural mesothelioma (ID1424)

In development [GID-TA10359] Expected publication date: TBC

Technology appraisal guidance In development

Osteoporosis (postmenopausal women) - abaloparatide [ID882]

In development [GID-TA10071] Expected publication date: TBC

Technology appraisal guidance In development

Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

In development [GID-TA10026] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]

In development [GID-TAG479] Expected publication date: TBC

Technology appraisal guidance In development

Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]

In development [GID-TA10448] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Nivolumab in combination for untreated advanced gastric cancer [ID1465]

In development [GID-TA10352] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605

In development [GID-TA10488] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Preterm labour and birth (update)

In development [GID-NG10078] Expected publication date: 02 August 2019

NICE guideline In development

Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]

In development [GID-TA10504] Expected publication date: TBC

Technology appraisal guidance In development

Acalabrutinib for treating chronic lymphocytic leukaemia ID1613

In development [GID-TA10532] Expected publication date: TBC

Technology appraisal guidance In development